These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21955161)

  • 1. Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1601-12. PubMed ID: 21955161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Cella D; Huang HQ; Monk BJ; Wenzel L; Benda J; McMeekin DS; Cohn D; Ramondetta L; Boardman CH
    Gynecol Oncol; 2010 Dec; 119(3):531-7. PubMed ID: 20837359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Thigpen T
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
    Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
    Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
    Monk BJ; Sill MW; McMeekin DS; Cohn DE; Ramondetta LM; Boardman CH; Benda J; Cella D
    J Clin Oncol; 2009 Oct; 27(28):4649-55. PubMed ID: 19720909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
    Dongiovanni D; Fissore C; Berruti A; Buffoni L; Addeo A; Barone C; Polimeni MA; Ottaviani D; Bertetto O; Dongiovanni V
    Lung Cancer; 2005 Feb; 47(2):269-75. PubMed ID: 15639726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
    J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
    Grossi F; Belvedere O; Fasola G; Barbone F; Rizzato S; Sibau A; Recchia L; Vigevani E; Ceschia T; Morelli A; Guglielmi A; Puglisi F; Follador A; Talmassons G; Sobrero AF
    Lung Cancer; 2004 Oct; 46(1):99-106. PubMed ID: 15364137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
    Bunn PA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
    Pujol JL; Barlesi F; Daurès JP
    Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
    J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.